Abstract:Background Phosphoinositide-3-kinase Delta (PI3K delta) plays a key role in B-cell signal transduction and inhibition of PI3K delta is confirmed to have clinical benefit in certain types of activation of B-cell malignancies. Virtual screening techniques have been used to discover new molecules for developing novel PI3K delta inhibitors with little side effects. Method: Computer aided drug design method were used to rapidly screen optimal PI3K delta inhibitors from the Asinex database. Virtual screening based molecular docking was performed to find novel and potential lead compound targeting PI3K delta, at first. Subsequently, drug likeness studies were carried out on the retrieved hits to evaluate and analyze their drug like properties such as absorption, distribution, metabolism, excretion, and toxicity (ADMET) for toxicity prediction. Three least toxic compounds were selected for the molecular dynamics (MD) simulations for 30 ns in order to validate its stability inside the active site of PI3K delta receptor. Results: Based on the present in silico analysis, two molecules have been identified which occupied the same binding pocket confirming the selection of active site. ASN 16296138 (Glide score: - 12.175 kcal/mol, cdocker binding energy: - 42.975 kcal/mol and Delta G(bind) value: - 90.457 kcal/mol) and HAS 00227397 (Glide score: - 10.988 kcal/mol, cdocker binding energy: - 39.3376 kcal/mol and Delta G(bind) value: - 81.953 kcal/mol) showed docking affinities comparatively much stronger than those of already reported known inhibitors against PI3K delta. These two ligand's behaviors also showed consistency during the simulation of protein-ligand complexes for 30000 ps respectively, which is indicative of its stability in the receptor pocket. Conclusion: Compound ASN 16296138 and BAS 00227397 are potential candidates for experimental validation of biological activity against PI3K delta in future drug discovery studies. This study smoothes the path for the development of novel leads with improved binding properties, high drug likeness, and low toxicity to humans for the treatment of cancer.

Identification of the potential dual inhibitor of protein tyrosine phosphatase sigma and leukocyte common antigen-related phosphatase by virtual screen, molecular dynamic simulations and post-analysis

Identification of novel inhibitor of protein tyrosine phosphatases delta: structure-based pharmacophore modeling, virtual screening, flexible docking, molecular dynamics simulation, and post-molecular dynamics analysis

Identification of novel PAD2 inhibitors using pharmacophore-based virtual screening, molecular docking, and MD simulation studies

Identification of potential leukocyte antigen-related protein (PTP-LAR) inhibitors through 3D QSAR pharmacophore-based virtual screening and molecular dynamics simulation

Identification of Phosphoinositide-3 Kinases Delta and Gamma Dual Inhibitors Based on the P110δ/γ Crystal Structure

Novel multi-drug delivery hydrogel using scar-homing liposomes improves spinal cord injury repair.

Mechanism Study of Polydatin in Treating Spinal Cord Injury by Modulating Mitochondrial Membrane Potential Based on Network Pharmacology and Molecular Docking

Identification of inhibitors for neurodegenerative diseases targeting dual leucine zipper kinase through virtual screening and molecular dynamics simulations

Identifying Potential Dual Inhibitory Candidates for Non-Small Cell Lung Cancer Through Molecular Docking, 3D-QSAR Pharmacophore-based Virtual Screening, Comparative Molecular Field and Similarity Indices Analysis Modeling

Mechanism Analysis of Selenium-Containing Compounds in Alleviating Spinal Cord Injury Based on Network Pharmacology and Molecular Docking Technology

Inhibition of phospholipase D promotes neurological function recovery and reduces neuroinflammation after spinal cord injury in mice

Network Pharmacology Analysis and Experimental Validation to Explore the Effect and Mechanism of Tetramethylpyrazine for Spinal Cord Injury

A Novel Artificial Intelligence Protocol to Investigate Potential Leads for Parkinson's Disease

Exploring New Potential Pkcθ Inhibitors Using Pharmacophore Modeling, Molecular Docking Analysis, and Molecular Dynamics Simulations

In-silico identification of new inhibitors for Low-density lipoprotein receptor-related protein6 (LRP6)

Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation

Identification of novel NLRP3 inhibitors as therapeutic options for epilepsy by machine learning-based virtual screening, molecular docking and biomolecular simulation studies

Identification of Natural Products As Dual Sphingosine Kinase-1 and Programmed Cell-Death 1-Inhibitors by Virtual Screening and Molecular Dynamics Simulation

Inhibition of striatal-enriched protein tyrosine phosphatase by targeting computationally revealed cryptic pockets

Identification of Novel PI3Kδ Inhibitors by Docking, ADMET Prediction and Molecular Dynamics Simulations.

Polydatin attenuated neuropathic pain and motor dysfunction following spinal cord injury in rats by employing its anti-inflammatory and antioxidant effects